NASDAQ: SLRNAcelyrin Inc Stock
$4.24+0.00 (+0%)
Updated Apr 26, 2024
SLRN Price
$4.24
Fair Value Price
$13.63
Market Cap
$417.07M
52 Week Low
$4.18
52 Week High
$29.88
P/E
-0.78x
P/B
0.64x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$381.64M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.13
Operating Cash Flow
-$170M
Beta
0.75
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SLRN Overview
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SLRN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SLRN ($4.24) is undervalued by 68.88% relative to our estimate of its Fair Value price of $13.63 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
SLRN ($4.24) is significantly undervalued by 68.88% relative to our estimate of its Fair Value price of $13.63 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
SLRN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SLRN due diligence checks available for Premium users.
Be the first to know about important SLRN news, forecast changes, insider trades & much more!
SLRN News
Valuation
SLRN fair value
Fair Value of SLRN stock based on Discounted Cash Flow (DCF)
Price
$4.24
Fair Value
$13.63
Undervalued by
68.88%
SLRN ($4.24) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SLRN ($4.24) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SLRN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SLRN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.78x
Industry
14.88x
Market
41.14x
SLRN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.64x
Industry
5.85x
SLRN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SLRN's financial health
Profit margin
Revenue
$0.0
Net Income
-$95.2M
Profit Margin
0%
SLRN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$742.7M
Liabilities
$86.4M
Debt to equity
0.13
SLRN's short-term assets ($736.64M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SLRN's short-term assets ($736.64M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SLRN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$73.6M
Investing
-$92.6M
Financing
$2.6M
SLRN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SLRN vs Biotech Stocks
Acelyrin Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.